"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD. In this video, Matthew J. Mutter, MD, highlights ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection through urine ...

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

ctDNA in metastatic RCC shows high concordance with disease progression and indolence in negative cases, indicating its prognostic value. A clinical trial is underway to explore treatment ...

All nine patients with stage III/IV ccRCC showed anti-tumor responses and remained disease-free three years post-vaccination. The vaccine induced durable T cell activation and immune responses against ...

“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R.

This video segment discusses the frequency of encountering mCRPC patients with hepatic dysfunction, additional tests to consider, and treatment options for these patients.

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.

Panelists discuss how for patients with BCG-unresponsive bladder cancer, treatment selection depends on key factors including tumor characteristics (carcinoma in situ vs papillary), patient fitness, ...

If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient? What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC? What ...